Radiolanthanides in endoradiotherapy: An overview

Radiochimica Acta

Volumn 95, Issue 6, 2007, Pages 303-311

  Rosch F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Bifunctional chelator; Endoradiotherapy; Labelling; Nuclear reaction; Radiation dosimetry; Radiolanthanides

Indexed keywords

EID: 34250724362     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2007.95.6.303     Document Type: Review

References (60)

1. Larson, S. M., Carrasquillo, J. A., Reynolds, J. C.: Radioimmunodetection and radioimmunotherapy. Cancer Invest. 2, 363 (1984).
2. Spencer, R. P., Seevers Jr., R. H., Friedman, A. M.: Radionuclides in Therapy. CRC Press, Boca Raton (1987).
3. Hoefnagel, C. A.: Radionuclide therapy revisited. Eur. J. Nucl. Med. 18, 408 (1991).
4. Volkert, W. A., Goeckeler, W. F., Erhardt, G. J., Ketring, A. R.: Therapeutic radionuclides: production and decay property considerations. J. Nucl. Med. 32, 174 (1991).
5. Volkert, W. A., Hoffman, T. J.: Therapeutic radiopharmaceuticals. Chem. Rev. 99, 2269 (1999).
6. Cutler, C. S., Smith, C. J., Ehrhardt, G. J., Tyler, T. T., Jurisson, S. S., Deutsch, E.: Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother. Radiopharm. 15, 531 (2000).
7. Zalutsky, M. R.: Radionuclide therapy. In: Handbook of Nuclear Chemistry. Vol. 4 (Vértes, A,. Nagy, S., Klencsár, Z., eds.) Kluwer Academic Publishers, The Netherlands (2003), p. 315.
8. Rösch, F., Forssell-Aronsson, E.: Radiolanthanides in nuclear medicine. In: Metal Ions and their Complexes in Medication. (Sigel, A., Sigel, H., Dekker, M., eds.) Inc. New York & Basel Eds. (2004), vol. 42, p. 77.
9. Bernhardt, P., Benjegard, S. A., Kolby, L., Johanson, V, Nilsson, O., Ahlman, H., Forssell-Aronsson, E.: Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int. J. Radiat. Oncol. Biol. Phys. 51, 514 (2001).
10. Uusijärvi, H., Bernhardt, P., Mäcke, H., Rösch, R, Forssell-Aronsson, E.: Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production. J. Nucl. Med. 47, 807 (2006).
11. Mirzadeh, S., Mausner, H.-J., Garland, M. A.: Reactor-produced medical radionuclides. In: Handbook of Nuclear Chemistry. Vol. 4 (Vértes, A,. Nagy, S., Klencsár, Z., eds.) Kluwer Academic Publishers, The Netherlands (2003), p. 1.
12. Qaim, S. M.: Cyclotron production of medical radionuclides. In: Handbook of Nuclear Chemistry. Vol. 4 (Vértes, A,. Nagy, S., Klencsár, Z., eds.) Kluwer Academic Publishers, The Netherlands (2003), p. 47.
13. Rösch, F., Knapp, F. F.: Radionuclide generators. In: Handbook of Nuclear Chemistry. Vol. 4 (Vértes, A,. Nagy, S., Klencsár, Z., eds.) Kluwer Academic Publishers, The Netherlands (2003), p. 81.
14. Jang, Y. H., Blanco, M., Dasgupta, S., Keire, D. A., Shively, J. E., Goddard, W. A. I.: Mechanism and energetics for complexation of Y-90 with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), a model for cancer radioimmunotherapy. J. Am. Chem. Soc. 121, 6142 (1999).
15. Sands, H., Jones, P. L., Shah, S. A., Palme, D., Vessele, R. L., Gallagher, B. M.: Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res. 48, 188 (1988)
16. Gridley, D. S., Ewart, K. L., Coa, J. D., Stickney, D. R.: Hyperthermia enhances localization of 111In-labeled hapten to bifunctional antibody in human colon tumor xenografts. Cancer Res. 51, 1515 (1991).
17. Zalutsky, M. R., Vaidyanathan, G.: Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr. Pharm. Design 6, 1433 (2000).
18. Langmuir, V.K, Sutherland, R. M.: Radiobiology of radioimmunotherapy: current status. Antibody Immunoconj. Radiopharm. 1, 195 (1988).
19. Allen, B. J., Blagojevic, N.: Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149. Nucl. Med. Commun. 17, 40 (1996).
20. Allen, B. J., Goozee, G., Iman, S., Leigh, J., Beyer, G.: Proceedings of the 6th International Conference on Radiopharmaceutical Dosimetry, Gatlinburg, TN (1996), p. 392.
21. Allen, B. J., Goozee, G., Sarkar, S., Beyer, G., Morel, C., Byrne, A. P.: Production of terbium-152 by heavy ion reactions and proton induced spallation. Appl. Radiat. Isotopes 54, 53 (2001).
22. 165Er process. Radiochim. Acta 92, 219 (2004).
23. Mäcke, H., Good, S.: Radiometals (non-Tc, non-Re) and bifunctional labelling chemistry. In: Handbook of Nuclear Chemistry. Vol. 4 (Vértes, A., Nagy, S., Klencsár, Z., eds.) Kluwer Academic Publishers, The Netherlands (2003), p. 279.
24. 90Y-labelled analogue. Eur. J. Nucl. Med. 26, 358 (1999).
25. Deutsch, E. J., Brodack, J. W., Deutsch, K. F.: Radiation synovectomy revisited. Eur. J. Nucl. Med. 20, 1113 (1993).
26. 165Dy-FHMA: lymph node uptake and radiation dosimetry calculations. Nucl. Med. Biol. 12, 457 (1986).
27. Ruotsi, A., Hypen, M., Rekonen, A., Oka, M.: Erbium-169 versus triamcinolone hexacetonide in the treatment of rheumatoid finger joints. Ann. Rhem. Disease 38, 45 (1979).
28. Song, J., Suh, C. H., Park, Y. B., Lee, S. H., Yoo, N. C., Lee, J. D., Kim, K. H., Lee S. K.: A phase I/IIa study on intra-articular injection of holmium-166-chitosan complex for the treatment of knee synovitis of rheumatoid arthritis. Eur. J. Nucl. Med. 28, 489 (2001).
29. 153Sm-chitosan complex for radiation synovectomy. Nucl. Med. Biol. 28, 719 (2001).
30. Chinol, M., Vallabhajosula, S., Goldsmith, S. J., Klein, M. J., Deutsch, K. F., Chinen, L. K., Brodack, J. W., Deutsch, E. A., Watson, B. A., Tofe, A. J.: Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxy apatite particles: potential radiopharmaceuticals for radiation synovectomy. J. Nucl. Med. 34, 1536 (1993).
31. Bayouth, J. E., Macey, D. J., Kasi, L. P., Garlich, J. R., McMillan, K., Dimopoulos, M. A., Champlin, R. E.: Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J. Nucl. Med. 36, 730 (1995).
32. 90Y radioimmunotherapy. Bioconj. Chem. 2, 187 (1991).
33. Brechbiel, M. W., Gansow, O. A., Atcher, R. W., Schlom, J., Esteban, J., Simpson, D. E., Colcher, D.: Synthesis of 1(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorg. Chem. 25, 2772 (1986).
34. Brockmann, J., Rösch, E: Determination of stability constants in Y-DTPA-peptide-systems: Evaluation of a radiochemical method using n.c.a. yttrium-88. Radiochim. Acta 87, 79 (1999).
35. Broan, C. J., Cox, J. P. L., Craig, A. S., Kataky, R., Parker, D., Harrison, A., Randall, A. M., Ferguson, G.: Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-ray molecular structure of the indium and gallium complexes of 1,4,7- triazacyclononane-1,4,7-triaceticacid. J. Chem. Soc. Perkin Trans. 2, 87(1991).
36. Loncin, M. F., Desreux, J. F., Merciny, E.: Coordination of lanthanides by two polyamino polycarboxylic macrocycles: formation of highly stable lanthanide complexes. Inorg. Chem. 25, 2646 (1986).
37. Ugur, O., Kostakoglu, L., Hui, E. T., Fisher, D. R., Garmestani, K., Gansow, O. A., Cheung, N. V., Larson, S. M.: Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. Nucl. Med. Biol. 23, 1 (1996).
38. Keana, J. F. W., Mann, J. S.: Chelating ligands functionalized for facile attachment to biomolecules. A convenient route to 4-isothiocyanatobenzyl derivatives of diethylenetriaminepentaacetic acid (DTPA) and ethylenediaminetetraacetic acid. J. Org. Chem. 55, 2868 (1990).
39. Roselli, M., Schlom, J., Gansow, O. A., Brechbiel, M. W., Mirzadeh, S., Pippin, C. G., Milenic, D. E., Colcher, D.: Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. Int. J. Radiat. Appl. Instrum. B 18, 389 (1991).
40. Cummins, C. H., Rutter Jr., E. W., Fordyce, W. A.: A convenient synthesis of bifunctional chelating agents based on diethylene-triaminepentaacetic acid and their coordination chemistry with yttrium(III). Bioconj. Chem. 2, 180 (1991).
41. Moi, M. K., DeNardo, S. J., Meares, C. E: Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. 50, 789 (1990).
42. Li, M., Meares, C. F.: Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconj. Chem. 4, 275 (1993).
43. Li, M., Meares, C. E, Zhong, G., Miers, L., Xiong, C. Y., De Nardo, S. J.: Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method. Bioconj. Chem. 5, 101 (1994).
44. Bhalgat, M. K., Roberts, J. C., Mercer-Smith, J. A., Knotts, B. D., Vessella, R. L., Lavallee, D. K.: Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin-A6H immunoconjugates. Nucl. Med. Biol. 24, 179 (1997).
45. De Jong, M., Valkema, R., Jamar, F., Kvols, L. K., Kwekkeboom, D. J., Breeman, W. A., Bakker, W. H., Smith, C., Pauwels, S., Krenning, E. P.: Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin. Nucl. Med. 32, 133 (2002).
46. 111In-DTPA]octreotide in patients. Eur. J. Nucl. Med. 28, 1319 (2001).
47. 3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int. J. Cancer 92, 628 (2001).
48. Hu, F., Cutler, C. S., Hoffman, T., Sieckman, G., Volkert, W. A., Jurisson, S. S.: Pm-149 DOTA bombesin analogs for potential radiotherapy. In vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14) NH(2). Nucl. Med. Biol. 29, 423 (2002).
49. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 20, 2754 (2005).
50. Schlom, J., Siler, K., Milenic, D. E., Eggensperger, D., Colcher, D., Miller, L. S., Houchens, D., Cheng, R., Kaplan, D., Goeckeler, W.: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. Cancer Res. 51, 2889 (1991).
51. Schott, M. E., Schlom, J., Siler, K., Milenic, D. E., Eggensperger, D., Colcher, D., Cheng, R., Kruper Jr., W. J., Fordyce, W., Goeckeler, W.: Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer 73, 993 (1994).
52. Macey, D. J., Meredith, R. F.: A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy. Clin. Cancer Res. 5, 3044s (1999).
53. Meredith, R. F., Partridge, E. E., Alvarez, R. D., Khazaeli, M. B., Plott, G., Russell, C. D., Wheeler, R. H., Liu, T., Grizzle, W. E., Schlom, J., LoBuglio, A. F.: Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37, 1491 (1996).
54. 177Lu-CC49: a phase I/II study. Gynecol. Oncol. 65, 94 (1997).
55. Meredith, R. F., Alvarez, R. D., Partridge, E. E., Khazaeli, M. B., Lin, C. Y, Macey, D. J., Austin Jr., J. M., Kilgore, L. C., Grizzle, W. E., Schlom, J., LoBuglio, A. F.: Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother. Radiopharm. 16, 305 (2001).
56. Stein, R., Govindan, S. V., Chen, S., Reed, L., Richel H., Griffiths, G. L., Hansen, H. J., Goldenberg, D. M.: Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of 177Lu and comparison of its efficacy with that of 90Y and residualizing 1311. J. Nucl. Med. 42, 967 (2001).
57. Kraeber-Bodere, F., Mishra, A., Thedrez, P., Faivre-Chauvet, A., Bardies, M., Imai, S., Le Boterff, J., Chatal, J. E: Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Eur. J. Nucl. Med. 23, 560 (1996).
58. Li, G. P., Zhang, H., Zhu, C. M.: Radioimmunotherapy with 153Sm-CEA monoclonal antibody in nude mice bearing human colon carcinoma: an experimental study. Di Yi Jun Yi Da Xue Xue Bao 23, 1 (2003).
59. Bugaj, J. E., Erion, J. L., Schmidt, M. A., Srinivasan, A.: Radiotherapeutic efficacy of (153)Sm-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats. Nucl. Med. Biol. 28, 327 (2001).
60. Browne, E., Firestone, R. B.: Table of Radioactive Isotopes. (Shirley, V S., ed.) Wiley, New York (1986).